Cohance Lifesciences to appoint Himanshu Agarwal as whole-time director and CFO

Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, announced a postal ballot to seek shareholder approval for the appointment of Himanshu Agarwal as its whole-time director. Agarwal will serve for a five-year term, from October 29, 2025, to October 28, 2030, also holding the position of chief financial officer. The board of directors, based on the Nomination and Remuneration Committee's recommendation, approved this appointment on October 28, 2025.

The remote e-voting period for this resolution will commence on December 24, 2025, at 9:00 a.m. (IST) and conclude on January 22, 2026, at 5:00 p.m. (IST). Voting results are expected to be declared by January 23, 2026. This postal ballot notice is being distributed electronically to eligible members as of the cut-off date, December 19, 2025.

Agarwal's remuneration for the financial year 2025-26 will include a fixed compensation of INR 3 Crores per annum and a variable compensation of INR 60 Lakhs per annum, subject to performance targets. From April 1, 2026, his fixed compensation is set to increase to INR 3.56 Crores per annum, with variable compensation rising to INR 71 Lakhs per annum.